Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Increasing SBP variability is associated with an increased risk of developing incident diabetic foot ulcers

Brennan, Meghan B.a; Guihan, Maryloub,c; Budiman-Mak, Ellyb,d; Kang, Hyojunge; Lobo, Jennifer M.f; Sutherland, Bryn L.a; Emanuele, Nicholasb,d; Huang, Elbert S.g; Sohn, Min-Woongf

doi: 10.1097/HJH.0000000000001783
ORIGINAL PAPERS: Blood pressure measurements
Buy
SDC

Objective: SBP variability may be a target for mitigating end-organ damage associated with vascular disease. We evaluated the relationship between increased SBP variability and risk of incident diabetic foot ulceration.

Methods: Using a nested case–control design, we followed patients diagnosed with diabetes and treated within the US Department of Veterans Affairs Healthcare system for development of a diabetic foot ulcer (event) between 2006 and 2010. Each case was randomly matched to up to five controls based on age, sex, race/ethnicity, and calendar time. SBP variability was computed using at least three blood pressure measurements from the year preceding the event. The association between SBP variability and foot ulceration was examined using conditional logistic regression. Potential protective effects of calcium channel blockers, which blunt SBP variability, were also explored.

Results: The study sample included 51 111 cases and 129 247 controls. Compared with those in quartile 1 (lowest variability), patients in quartiles 2–4 had higher adjusted odds ratios for diabetic foot ulcer development: 1.11 (95% CI 1.07–1.16), 1.20 (95% CI 1.15–1.25), 1.29 (95% CI 1.24–1.34) (P for trend <0.001). Calcium channel blockers were associated with reduced risks of ulceration for those without peripheral vascular disease (OR = 0.87, 95% CI 0.84–0.90, P < 0.001) or neuropathy (OR = 0.85, 95% CI 0.82–0.89, P < 0.001) in adjusted subgroup analyses.

Conclusion: This study describes a graded relationship between SBP variability and risk of diabetic foot ulceration, providing a potential new and modifiable target to reduce this common complication.

aHealth Innovation Program, University of Wisconsin, Madison, Wisconsin

bCenter of Innovation for Complex Chronic Healthcare, Hines VA Hospital, Hines

cFeinberg School of Medicine, Northwestern University

dStritch School of Medicine, Loyola University, Maywood, Illinois

eDepartment of Systems and Information Engineering, School of Engineering

fDepartment of Public Health Sciences, School of Medicine, University of Virginia, Charlottesville, Virginia

gDepartment of Medicine, Pritzker School of Medicine, University of Chicago, Chicago, Illinois, USA

Correspondence to Min-Woong Sohn, Department of Public Health Sciences, Hospital West, 3rd Floor, Room 3181, Charlottesville, VA 22908-0717, USA. Tel: +1 434 924 8753; fax: +1 434 243 5787; e-mail: msohn@virginia.edu

Received 26 January, 2018

Revised 28 March, 2018

Accepted 11 April, 2018

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.jhypertension.com).

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.